Floatz logo

Therapeutic Asset Ratings

470 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Toripalimab
Immune-related Adverse Event
Sun Yat-sen UniversityP2CCC (53)
Toripalimab
Pancreatic Adenocarcinoma
Sun Yat-sen UniversityP2CCC (53)
Toripalimab
Microsatellite Instability High
Sun Yat-sen UniversityP2CCC (53)
Toripalimab
Mismatch Repair Deficiency
Sun Yat-sen UniversityP2CCC (53)
Toripalimab
Mismatch Repair-deficient (dMMR)
Sun Yat-sen UniversityP2CCC (53)
Toripalimab
Marinesco-Sjogren Syndrome
Sun Yat-sen UniversityP2CCC (53)
Toripalimab
Surufatinib
Sun Yat-sen UniversityP2CCC (53)
Trifluorouracil Tepidopyrimidine
Cancer
Sun Yat-sen UniversityP2CCC (53)
Trifluorouracil Tepidopyrimidine
Radiotherapy, Intensity-Modulated
Sun Yat-sen UniversityP2CCC (53)
Trifluorouracil Tepidopyrimidine
Targeted Therapy
Sun Yat-sen UniversityP2CCC (53)
Trilaciclib
Diffuse Large B-Cell Lymphoma
Sun Yat-sen UniversityP2CCC (53)
Trilaciclib
Head And Neck Squamous Cell Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Tuvonralimab
Neoadjuvant Chemoimmunotherapy
Sun Yat-sen UniversityP2CCC (53)
Tuvonralimab
Rectal Cancer
Sun Yat-sen UniversityP2CCC (53)
(+)-VINCRISTINE
CD5 Positive
Sun Yat-sen UniversityP2CCC (53)
(+)-VINCRISTINE
Ivonescimab
Sun Yat-sen UniversityP2CCC (53)
(+)-VINCRISTINE
Radiotherapy, Intensity-Modulated
Sun Yat-sen UniversityP2CCC (53)
VOLITINIB
Mutation
Sun Yat-sen UniversityP2CCC (53)
Vorolanib
Nonpapillary Renal Cell Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Vorolanib
Vorolanib
Sun Yat-sen UniversityP2CCC (53)
Yivoximab
Nonpapillary Renal Cell Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Yivoximab
Renal Cell Carcinoma
Sun Yat-sen UniversityP2CCC (53)
Zanubrutinib
MSS Metastatic Colorectal Cancer
Sun Yat-sen UniversityP2CCC (53)
Zanubrutinib
Peritoneal Metastasis
Sun Yat-sen UniversityP2CCC (53)
Zanubrutinib
Peritoneal (Metastatic) Cancer
Sun Yat-sen UniversityP2CCC (53)
Showing 276 to 300 of 470 assets
PreviousPage 12 of 19Next